Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations -- In honor of 20 years of targeted protein degradation, Arvinas announces $25,000 prize to recognize the efforts of an up-and-coming researcher in the field of targeted protein degradation – --...

Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021 NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...

Arvinas Appoints Linda Bain to its Board of Directors NEW HAVEN, Conn., June 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...